| Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial P Ost, D Reynders, K Decaestecker, V Fonteyne, N Lumen, A De Bruycker, ... Journal of Clinical Oncology 36 (5), 446-453, 2018 | 1259 | 2018 |
| Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature P Ost, A Bossi, K Decaestecker, G De Meerleer, G Giannarini, RJ Karnes, ... European urology 67 (5), 852-863, 2015 | 391 | 2015 |
| Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence K Decaestecker, G De Meerleer, B Lambert, L Delrue, V Fonteyne, ... Radiation oncology 9, 1-10, 2014 | 271 | 2014 |
| Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy P Berkovic, G De Meerleer, L Delrue, B Lambert, V Fonteyne, N Lumen, ... Clinical genitourinary cancer 11 (1), 27-32, 2013 | 218 | 2013 |
| EAU-ESMO Consensus statements on the management of advanced and variant bladder cancer—an international collaborative multistakeholder effort†: under the auspices of the EAU … JA Witjes, M Babjuk, J Bellmunt, HM Bruins, TM De Reijke, M De Santis, ... European urology 77 (2), 223-250, 2020 | 201 | 2020 |
| Impact of sex reassignment surgery on lower urinary tract function P Hoebeke, G Selvaggi, P Ceulemans, G De Cuypere, G T'Sjoen, ... European urology 47 (3), 398-402, 2005 | 181 | 2005 |
| Enhanced recovery after robot-assisted radical cystectomy: EAU robotic urology section scientific working group consensus view JW Collins, H Patel, C Adding, M Annerstedt, P Dasgupta, SM Khan, ... European urology 70 (4), 649-660, 2016 | 166 | 2016 |
| Erectile implants in female-to-male transsexuals: our experience in 129 patients PB Hoebeke, K Decaestecker, M Beysens, Y Opdenakker, N Lumen, ... European urology 57 (2), 334-341, 2010 | 161 | 2010 |
| Prognostic factors influencing prostate cancer‐specific survival in non‐castrate patients with metastatic prostate cancer P Ost, K Decaestecker, B Lambert, V Fonteyne, L Delrue, N Lumen, ... The Prostate 74 (3), 297-305, 2014 | 154 | 2014 |
| Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials MP Deek, K Van der Eecken, P Sutera, RA Deek, V Fonteyne, AA Mendes, ... Journal of clinical oncology 40 (29), 3377-3382, 2022 | 152 | 2022 |
| Robot-assisted kidney transplantation: the European experience A Breda, A Territo, L Gausa, V Tuğcu, A Alcaraz, M Musquera, ... European urology 73 (2), 273-281, 2018 | 147 | 2018 |
| Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial K Decaestecker, G De Meerleer, F Ameye, V Fonteyne, B Lambert, ... BMC cancer 14, 1-6, 2014 | 143 | 2014 |
| Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study AO Siefker-Radtke, A Necchi, SH Park, J García-Donas, RA Huddart, ... The Lancet Oncology 23 (2), 248-258, 2022 | 138 | 2022 |
| Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. P Ost, D Reynders, K Decaestecker, V Fonteyne, N Lumen, A De Bruycker, ... Journal of Clinical Oncology 38 (6_suppl), 10-10, 2020 | 128 | 2020 |
| Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma N Sundahl, G Vandekerkhove, K Decaestecker, A Meireson, ... European urology 75 (5), 707-711, 2019 | 113 | 2019 |
| Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control … T Steuber, C Jilg, P Tennstedt, A De Bruycker, D Tilki, K Decaestecker, ... European urology focus 5 (6), 1007-1013, 2019 | 112 | 2019 |
| Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant … P De Visschere, N Lumen, P Ost, K Decaestecker, E Pattyn, G Villeirs Clinical radiology 72 (1), 23-32, 2017 | 102 | 2017 |
| EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU … A Horwich, M Babjuk, J Bellmunt, HM Bruins, TM De Reijke, M De Santis, ... Annals of Oncology 30 (11), 1697-1727, 2019 | 93 | 2019 |
| Managing the adverse events of intravesical bacillus Calmette–Guérin therapy K Decaestecker, W Oosterlinck Research and reports in urology, 157-163, 2015 | 83 | 2015 |
| Learning curve in robot-assisted kidney transplantation: results from the European Robotic Urological Society Working Group A Gallioli, A Territo, R Boissier, R Campi, G Vignolini, M Musquera, ... European urology 78 (2), 239-247, 2020 | 82 | 2020 |
